GSK plc (NYSE:GSK) Shares Bought by Sivia Capital Partners LLC

Sivia Capital Partners LLC grew its stake in GSK plc (NYSE:GSK) by 29.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,610 shares of the pharmaceutical company’s stock after acquiring an additional 1,507 shares during the period. Sivia Capital Partners LLC’s holdings in GSK were worth $224,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of GSK. Eastern Bank acquired a new stake in GSK in the third quarter valued at $26,000. ST Germain D J Co. Inc. grew its holdings in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. raised its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the 2nd quarter valued at $37,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

NYSE GSK traded down $0.41 during midday trading on Monday, hitting $32.68. The company had a trading volume of 3,887,908 shares, compared to its average volume of 3,069,380. GSK plc has a fifty-two week low of $32.55 and a fifty-two week high of $45.92. The stock has a market cap of $67.73 billion, a price-to-earnings ratio of 21.22, a P/E/G ratio of 1.52 and a beta of 0.63. The firm has a fifty day simple moving average of $34.38 and a two-hundred day simple moving average of $38.17. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.81%. GSK’s dividend payout ratio is presently 95.45%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on GSK shares. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.